ArticleIn silico pharmacology2025
Molecular Docking and dynamic simulation analysis of flavonoid derivatives as COX-2 inhibitors.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Green synthesis of pyridine-benzofuran hybrids with anti-inflammatory activity alongsideiScience · 2026Article
- Chemical Characterization and Pharmacological Activity of Byrsonima crassifolia (L.) Kunth (Murici): Antinociceptive Effects, Edema Reduction, and Molecular Docking.Chemistry & biodiversity · 2026Article
- Phytochemical profiling and integrated in vitro and in silico assessment of the antioxidant, thrombolytic, and anti-inflammatory properties of Urena lobata L. leaf extracts.Scientific reports · 2026Article
- Development and Evaluation of a Baicalin-loaded Phytosomal Transdermal Patch for Type 2 Diabetes Mellitus.Current drug metabolism · 2026Article
- Pharmacological and molecular insights into linalool-richVeterinary world · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: Cyclooxygenase-2 (COX-2) is a key enzyme involved in inflammation and tumor progression, playing a significant role in the development of various cancers, including colorectal, breast, lung, and prostate cancers. In this study, molecular docking and molecular dynamics (MD) simulations were conducted to evaluate the binding potential and stability of flavonoid compounds as potential COX-2 inhibitors. A total of 36 flavonoid compounds were selected based on pharmacokinetic properties and subjected to molecular docking analysis. Binding affinity calculations revealed that several flavonoids exhibited strong interactions with COX-2, with Cudraflavone A showing the highest binding affinity of - 10.19 kcal/mol, surpassing the standard inhibitor Rofecoxib (- 9.4 kcal/mol). Key interactions were identified with critical active site residues, including Tyr130, Glu465, and Arg44, through hydrogen bonding and hydrophobic interactions. To further assess the stability of the COX-2-flavonoid complex, molecular dynamics simulations were performed using GROMACS. Root-mean-square deviation (RMSD) analysis demonstrated that the COX-2-Cudraflavone A complex exhibited greater structural stability compared to the unbound enzyme. Root-mean-square fluctuation (RMSF) analysis indicated reduced flexibility in key regions of the enzyme upon ligand binding, reinforcing its stabilizing effect. Additionally, the radius of gyration (Rg) analysis confirmed that the complex maintained a more compact conformation, suggesting enhanced structural integrity. These findings suggest that Cudraflavone A is a promising candidate for COX-2 inhibition, exhibiting superior binding affinity and stabilizing effects. This study provides valuable insights into the potential development of flavonoid-based COX-2 inhibitors for cancer and anti-inflammatory therapeutics. Graphic abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00349-x.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.